**Supplemental Digital Content 1.** Study Population

A total of 180 infants were enrolled at 41 sites (May 2014–December 2016); 178 infants received at least one dose of study drug; of these, 127 (71%) were randomized and 51 (29%) were in non-randomized arms.

## **90 Day Post-Treatment:**

## **Secondary Outcomes of Special Interest Assessment**

## **30 Day Post-Treatment:**

## **Primary Safety Outcome and Secondary Efficacy Outcomes**

Number completed (n=12)
Lost to follow-up (n=20)

 Death (n=2)

 Transfer or discharge (n=18)

## **Group 2**

**Ampicillin + Gentamicin + Clindamycin**

Number completed (n=32)

Lost to follow-up (n=14)

 Death (n=3)

 Transfer or discharge (n=11)

Allocated to intervention (n=47)

 Randomized (n=41)

 Received allocated intervention (n=46)

Did not receive allocated intervention/

 Enrolled not dosed (n=1)

## **Group 1**

**Ampicillin + Gentamicin + Metronidazole**

Allocated to intervention (n=63)

 Randomized (n=45)

  Received allocated intervention (n=62)

  Did not receive allocated intervention/ Enrolled not dosed (n=1)

Number completed (n=48)

Lost to follow-up (n=14)

 Death (n=5)

 Transfer or discharge (n=8)

 Consent withdrawn (n=1)

Number completed (n=28)
Lost to follow-up (n=20)

 Death (n=0)

 Transfer or discharge (n=20)

180 Enrolled

Number completed (n=23)
Lost to follow-up (n=31)

 Death (n=1)

 Transfer or discharge (n=30)

Allocated to intervention (n=70)

 Randomized (n=42)

Received allocated intervention (n=70)

## **Group 2**

**Piperacillin/Tazobactam + Gentamicin**

Number completed (n=54)

Lost to follow-up (n=16)

 Death (n=6)

 Transfer or discharge (n=10)